Chardan Capital Lowers Unity Biotechnology (NASDAQ:UBX) Price Target to $4.00
Unity Biotechnology (NASDAQ:UBX – Get Free Report) had its price objective cut by research analysts at Chardan Capital from $6.00 to $4.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Chardan Capital’s price target would suggest a potential upside of 233.33% from the stock’s previous […]
Unity Biotechnology (NASDAQ:UBX – Get Free Report) had its price objective cut by research analysts at Chardan Capital from $6.00 to $4.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Chardan Capital’s price target would suggest a potential upside of 233.33% from the stock’s previous […]
